Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related DSW
Wall Street Analysts Add To DSW's Tumble
Sellers Stepping All Over DSW After Q2 Report
Related PFE
Bayer's Latest Stage 2 Trial Could Be A Boon For Shares
S&P 500 Index Futures Trading Lower In Choppy, Volatile Session
Should You Sell GE, AT&T, Pfizer? Check Weekly Charts (Investor's Business Daily)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
Aug 2015Morgan StanleyReiteratesUnderweight
Aug 2015SusquehannaMaintainsPositive
Aug 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

Get Benzinga's Newsletters